Fig. 4. Interleukin-13 contributes to disruption of BBB and loss of astrocytes and in LPS-injected rat striatum in vivo. (A~C) Animals unilaterally received intrastriatal injection of PBS as a control (A) or LPS+IgG (B) or IL-13NA (C). 3 days later, FITC-labeled albumin was administered to detect focal leakage of the BBB. (D) Quantification of BBB leakage density. #p<0.001, as compared with PBS, *p<0.001, as compared with LPS+IgG. One-way ANOVA and Newman–Keuls analyses. Three to four animals were used for each experimental group. The results represent mean±SEM. (E~H) Animals unilaterally received intrastriatal injection of PBS as a control (E) or LPS only (F) or LPS+IgG (G) or LPS+IL-13NA (H). 3 days later, striatal tissues were immunostained with anti-GFAP antibody for astrocyte. Dotted round indicates area lacking in GFAP+ astrocytes. Arrow indicates syringe track. (I) Quantification of GFAP immunonegative (GFAP-) area at 7 days after LPS injection. #p<0.001, as compared with PBS, *p<0.001, as compared with LPS+IgG. One-way ANOVA and Newman–Keuls analyses. Four animals were used for each experimental group. The results represent mean±SEM. Scale bars, (A~C) 500 µm; (E~H) 100 µm.
© Exp Neurobiol
